Lundin Law PC announces it is investigating claims against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (Nasdaq: RGLS) concerning possible violations of federal securities laws.
To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the Company’s June 27, 2016 announcement that it received verbal notice from the U.S. Food and Drug Administration (“FDA”) that the FDA placed the Company’s new investigational drug, for treatment of chronic hepatitis C virus infection, on clinical hold after a second serious case of jaundice was reported. Following this news, shares of Regulus dropped sharply.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160628006519/en/
Contacts:
Brian Lundin, Esq.
888-713-1033
Facsimile:
888-713-1125
brian@lundinlawpc.com
